Nonpharmacological Treatment of Hypercholesterolemia Increases Circulating Endothelial Progenitor Cell Population in Adults
2006; Lippincott Williams & Wilkins; Volume: 26; Issue: 5 Linguagem: Inglês
10.1161/01.atv.0000218504.71680.b5
ISSN1524-4636
AutoresGiuseppe Croce, Gabriella Passacquale, Stefano Necozione, Claudio Ferri, Giovambattista Desideri,
Tópico(s)Lymphatic System and Diseases
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 26, No. 5Nonpharmacological Treatment of Hypercholesterolemia Increases Circulating Endothelial Progenitor Cell Population in Adults Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBNonpharmacological Treatment of Hypercholesterolemia Increases Circulating Endothelial Progenitor Cell Population in Adults Giuseppe Croce, Gabriella Passacquale, Stefano Necozione, Claudio Ferri and Giovambattista Desideri Giuseppe CroceGiuseppe Croce Department of Internal Medicine and Public Health, University of L'Aquila, Italy , Gabriella PassacqualeGabriella Passacquale Department of Internal Medicine and Public Health, University of L'Aquila, Italy , Stefano NecozioneStefano Necozione Department of Internal Medicine and Public Health, University of L'Aquila, Italy , Claudio FerriClaudio Ferri Department of Internal Medicine and Public Health, University of L'Aquila, Italy and Giovambattista DesideriGiovambattista Desideri Department of Internal Medicine and Public Health, University of L'Aquila, Italy Originally published1 May 2006https://doi.org/10.1161/01.ATV.0000218504.71680.b5Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:e38–e39To the Editor:Hypercholesterolemia represents a major cardiovascular risk factor because of its ability to promote and sustain proatherogenic inflammation of vascular wall.1 A reduction of number and activity of bone marrow–derived endothelial progenitor cells (EPCs) could participate in the development of vascular damage in hypercholesterolemic patients.2 Indeed, EPCs serve as a cellular reservoir to replace dysfunctional endothelium and to form a cellular patch at the site of denuding injury.3 According to this, the level of circulating EPCs predicts the occurrence of cardiovascular events and death from cardiovascular causes.4 Nonpharmacological treatment represents the first-line approach to primary prevention in hypercholesterolemia because of its effects on lipid profile and cardiovascular outcomes.5 Despite the wealth of evidence derived from epidemiological and interventional trials, there is limited understanding of the underlying molecular mechanisms. To clarify this topic, we evaluated whether or not changes in dietary habits, alone or in association with regular physical activity, were able to affect the number of circulating EPCs in patients with isolated hypercholesterolemia.We studied 38 never-treated hypercholesterolemic patients (LDL cholesterol between 4.1 and 4.9 mmol/L) without additional cardiovascular risk factors and/or concomitant diseases, including clinical conditions in which neovascularization might be present, such as cardiovascular disease, retinopathy, wound healing, or cancer. Patients were consecutively recruited among those who met the above criteria and referred to our Outpatient Unit for Cardiovascular Prevention between October 2004 and June 2005. After enrollment, all patients were randomly assigned to a 4-week treatment period based either on diet alone (10F/10M, 46.8±8.3 years) or on diet+physical training (8F/10M, 47.8±6.2 years). For this purpose, dietitians provided individualized dietary counseling aiming to indicate acceptable substitutions for favorite foods contributing to increase LDL cholesterol, according to Adult Treatment Panel III – Therapeutic Lifestyle Changes.5 For physical training, patients were asked to exercise daily for 30 minutes (including 5-minute warm-up and cool-down periods during each session, respectively) on a bicycle ergometer at 50% to 70% of their maximum heart rate.6At baseline and after the intervention period blood samples were taken for routine hematochemical check and assessment of circulating number of EPCs. For this purpose, mononuclear cells were isolated using Ficoll density-gradient centrifugation from 20 mL of peripheral blood, washed three times in PBS, resuspended in EGM-2 Bullet kit (Cambrex, Milan, Italy). Then, 106 mononuclear cells per cm2 were seeded on fibronectin-coated culture dishes (Becton & Dickinson). After 4 days of culture, nonadherent cells were discarded by washing with PBS while adherent cells were maintained in culture for further 3 days and then underwent cytochemical analysis. To confirm the EPC phenotype, adherent cells were incubated with DiI-labeled acLDL (Molecular Probes), at a concentration of 2.4 μg/mL for 1 hour at 37°C. Cells were then fixed with 1% paraformaldehyde for 10 minutes and incubated with fluorescein isothiocyanate (FITC)-labeled Ulex europaeus agglutinin I (Ulex-lectin; Sigma) at a concentration of 10 μg/mL for 1 hour. Dual-staining cells positive for both DiI-acLDL and FITC-labeled Ulex-lectin were judged as EPCs.7 EPCs were counted manually in 10 randomly selected microscopic fields by two independent investigators with an inverted fluorescent microscope (×20).Compared with baseline, two factor analysis of variance for repeated measures on one factor demonstrated a significant increase of EPC number in both treatment groups (Figure, panel A). Increments of EPCs were more evident in patients on diet+physical activity than in those on diet alone (Figure, panel A). LDL cholesterol levels significantly decreased after 4 weeks under both nonpharmacological treatment strategies being the decrement more evident in patients on diet+physical activity than in those on diet alone (Figure, panel B). Serum HDL cholesterol levels increased (P<0.04) while serum triglyceride concentrations decreased (P<0.004) in both treatment groups. Spearman nonparametric correlation showed a significant inverse relationship between treatment-induced changes in serum LDL cholesterol concentrations and circulating EPC number in the whole hypercholesterolemic population (Figure, panel C). In a multivariate regression analysis with a stepwise approach the reduction of serum LDL cholesterol concentrations independently predicted changes in EPC number (r2=0.19, P=0.0056). Download figureDownload PowerPointUpper panels depict the effects of a lipid-lowering diet, either alone (O) or combined with physical exercise (□), on the number of circulating endothelial progenitor cells (A) and serum LDL cholesterol concentrations (B) in 38 hypercholesterolemic patients (symbols indicate means, vertical bars indicate standard deviation). Panel C shows the relationship between treatment-induced changes in circulating endothelial progenitor cell number and serum LDL cholesterol levels in the combined two patient groups.Our study provides the first evidence that a nonpharmacological approach to hypercholesterolemia is associated with a significant increase of circulating EPC number in adults. This effect is more evident if dietary intervention is combined with physical training and mainly depends on LDL cholesterol reduction. In this regard, it is worth mentioning the recent demonstration that oxidized LDLs interfere with differentiation8 while increasing senescence9 of EPCs, thus potentially reducing their circulating pool. Because hypercholesterolemia is associated with increased lipid peroxidation,10,11 it is intriguing to speculate that a reduction of oxidative stress after nonpharmacological correction of hypercholesterolemia could have played a role in the observed increase in EPC population.Considering the suggested critical role of EPCs in restoring and maintaining multiple endothelial functions and counteracting atherogenesis and acute vascular complications of atherosclerosis,3 our findings shed new light on the mechanisms underlying the observed benefits deriving from a healthy lifestyle in hypercholesterolemic patients.51 Desideri G, Ferri C. Endothelial activation. Sliding door to atherosclerosis. Curr Pharm Des. 2005; 11: 2163–2175.CrossrefMedlineGoogle Scholar2 Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH, Zhu JH. Number and activity of endothelial progenitor cells from pheripheral blood in patients with hypercholesterolaemia. Clin Sci. 2004; 107: 273–280.CrossrefMedlineGoogle Scholar3 Urbich C, Dimmeler S. Endothelial progenitor cells. Characterization and vascular biology. Circ Res. 2004; 95: 343–353.LinkGoogle Scholar4 Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Eng J Med. 2005; 353: 999–1007.CrossrefMedlineGoogle Scholar5 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002; 106: 3143–3421.LinkGoogle Scholar6 Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, Froelicher VF, Leon AS, Pina IL, Rodney R, Simons-Morton DA, Williams MA, Bazzarre T. Exercise standards for testing and training. A statement for healthcare professionals from the American Heart Association. Circulation. 2001; 104: 1694–1740.CrossrefMedlineGoogle Scholar7 Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000; 97: 3422–3427.CrossrefMedlineGoogle Scholar8 Imanishi T, Hano T, Matsuo Y, Nishio I. Oxidized low-density lipoprotein inhibits vascular endothelial growth factor-induced endothelial progenitor cell differentiation. Clin Exp Pharmacol Physiol. 2003; 30: 665–670.CrossrefMedlineGoogle Scholar9 Imanishi T, Hano T, Sawamura T, Nishio I. Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clin Exp Pharmacol Physiol. 2004; 31: 407–413.CrossrefMedlineGoogle Scholar10 Davì G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB, Ciabattoni G, Patrono C. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997; 17: 3230–3235.CrossrefMedlineGoogle Scholar11 Desideri G, Croce G, Tucci M, Passacquale G, Broccoletti S, Valeri L, Santucci A, Ferri C. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab. 2003; 88: 5341–5347.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Balistreri C (2017) Endothelial Progenitor Cells and Their Clinical Applications as Potential Disease Biomarkers and Therapeutic Agents: Evidence and Controversies Regarding Their Effectiveness Endothelial Progenitor Cells, 10.1007/978-3-319-55107-4_2, (37-66), . Ichim T, Warbington T, Cristea O, Chin J and Patel A (2013) Intracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction?, Journal of Translational Medicine, 10.1186/1479-5876-11-139, 11:1, Online publication date: 1-Dec-2013. Cubbon R, Mercer B, Sengupta A and Kearney M (2013) Importance of insulin resistance to vascular repair and regeneration, Free Radical Biology and Medicine, 10.1016/j.freeradbiomed.2013.02.028, 60, (246-263), Online publication date: 1-Jul-2013. Zhao Y, Yuan B, Chen J, Feng D, Zhao B, Qin C and Chen Y (2012) Endothelial Progenitor Cells: Therapeutic Perspective for Ischemic Stroke, CNS Neuroscience & Therapeutics, 10.1111/cns.12040, 19:2, (67-75), Online publication date: 1-Feb-2013. Hazra S, Rasheed A, Bhatwadekar A, Wang X, Shaw L, Patel M, Caballero S, Magomedova L, Solis N, Yan Y, Wang W, Thinschmidt J, Verma A, Li Q, Levi M, Cummins C and Grant M (2012) Liver X Receptor Modulates Diabetic Retinopathy Outcome in a Mouse Model of Streptozotocin-Induced Diabetes, Diabetes, 10.2337/db11-1596, 61:12, (3270-3279), Online publication date: 1-Dec-2012. Fabbri-Arrigoni F, Clarke L, Wang G, Charakida M, Ellins E, Halliday N, Brogan P, Deanfield J, Halcox J and Klein N (2012) Levels of circulating endothelial cells and colony-forming units are influenced by age and dyslipidemia, Pediatric Research, 10.1038/pr.2012.76, 72:3, (299-304), Online publication date: 1-Sep-2012. Yao L, Heuser‐Baker J, Herlea‐Pana O, Iida R, Wang Q, Zou M and Barlic‐Dicen J (2012) Bone Marrow Endothelial Progenitors Augment Atherosclerotic Plaque Regression in a Mouse Model of Plasma Lipid Lowering, STEM CELLS, 10.1002/stem.1256, 30:12, (2720-2731), Online publication date: 1-Dec-2012. Sen S, McDonald S, Coates P and Bonder C (2010) Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease, Clinical Science, 10.1042/CS20100429, 120:7, (263-283), Online publication date: 1-Apr-2011. van Ramshorst J, Rodrigo S, Schalij M, Beeres S, Bax J and Atsma D (2011) Bone Marrow Cell Injection for Chronic Myocardial Ischemia: The Past and the Future, Journal of Cardiovascular Translational Research, 10.1007/s12265-010-9249-8, 4:2, (182-191), Online publication date: 1-Apr-2011. Fadini G and Avogaro A (2010) Potential manipulation of endothelial progenitor cells in diabetes and its complications, Diabetes, Obesity and Metabolism, 10.1111/j.1463-1326.2010.01210.x, 12:7, (570-583) Schmidt-Lucke C, Fichtlscherer S, Rössig L, Kämper U and Dimmeler S (2010) Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy, Atherosclerosis, 10.1016/j.atherosclerosis.2010.02.007, 211:1, (249-254), Online publication date: 1-Jul-2010. Mano R, Ishida A, Ohya Y, Todoriki H and Takishita S (2009) Dietary intervention with Okinawan vegetables increased circulating endothelial progenitor cells in healthy young women, Atherosclerosis, 10.1016/j.atherosclerosis.2008.09.035, 204:2, (544-548), Online publication date: 1-Jun-2009. Pirro M, Schillaci G, Romagno P, Mannarino M, Bagaglia F, Razzi R, Pasqualini L, Vaudo G and Mannarino E (2009) Influence of Short-term Rosuvastatin Therapy on Endothelial Progenitor Cells and Endothelial Function, Journal of Cardiovascular Pharmacology and Therapeutics, 10.1177/1074248408331021, 14:1, (14-21), Online publication date: 1-Mar-2009. Mancuso P, Peccatori F, Rocca A, Calleri A, Antoniotti P, Rabascio C, Saronni L, Zorzino L, Sandri M, Zubani A and Bertolini F (2009) Circulating Endothelial Cell Number and Viability Are Reduced by Exposure to High Altitude, Endothelium, 10.1080/10623320802092344, 15:1-2, (53-58), Online publication date: 1-Jan-2008. Pirro M, Bagaglia F, Paoletti L, Razzi R and Mannarino M (2008) Review: Hypercholesterolemia-associated endothelial progenitor cell dysfunction, Therapeutic Advances in Cardiovascular Disease, 10.1177/1753944708094769, 2:5, (329-339), Online publication date: 1-Oct-2008. Yang Z, Wang J, Wang L, Chen L, Tu C, Luo C, Tang A, Wang S and Tao J (2007) In vitro shear stress modulates antithrombogenic potentials of human endothelial progenitor cells, Journal of Thrombosis and Thrombolysis, 10.1007/s11239-006-9045-0, 23:2, (121-127), Online publication date: 13-Mar-2007. Yang Z, Wang J, Chen L, Luo C, Tang A and Tao J (2007) Acute exercise-induced nitric oxide production contributes to upregulation of circulating endothelial progenitor cells in healthy subjects, Journal of Human Hypertension, 10.1038/sj.jhh.1002171, 21:6, (452-460), Online publication date: 1-Jun-2007. Fadini G, Maruyama S, Ozaki T, Taguchi A, Meigs J, Dimmeler S, Zeiher A, de Kreutzenberg S, Avogaro A, Nickenig G, Schmidt-Lucke C, Werner N and Kiechl S (2010) Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis, PLoS ONE, 10.1371/journal.pone.0011488, 5:7, (e11488) Westerweel P, Visseren F, Hajer G, Olijhoek J, Hoefer I, de Bree P, Rafii S, Doevendans P and Verhaar M (2008) Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy, European Heart Journal, 10.1093/eurheartj/ehn431, 29:22, (2808-2817) May 2006Vol 26, Issue 5 Advertisement Article InformationMetrics https://doi.org/10.1161/01.ATV.0000218504.71680.b5PMID: 16627813 Originally publishedMay 1, 2006 PDF download Advertisement
Referência(s)